Global collaboration founded by Bristol-Myers
Squibb in 2012 now includes 16 leading academic institutions
The II-ON brings industry and academia together
with the goal of advancing Immuno-Oncology research
Bristol-Myers Squibb Company (NYSE:BMY) today announced that
Yale Cancer Center has joined the International Immuno-Oncology
Network (II-ON), a global peer-to-peer collaboration between
Bristol-Myers Squibb and academia that aims to advance
translational Immuno-Oncology (I-O) science. Formed in 2012 by
Bristol-Myers Squibb, the II-ON was one of the first networks to
bring academia and industry together to further the scientific
understanding of I-O, and has since expanded from 10 to 16 sites
across North America, Europe, Japan and Australia. Today, the
partners collaborate to generate innovative I-O science, launch
biology-driven trials and apply cutting-edge technologies with the
goal of translating research findings into clinical trials and,
ultimately, supporting efforts to improve survival outcomes across
tumor types.
“The II-ON gives us the chance to work more efficiently and
collaboratively with Bristol-Myers Squibb and the other II-ON
academic centers to address scientific questions in I-O,” said Roy
Herbst, M.D., Ph.D., director of the Center of Immuno-Oncology at
Yale Cancer Center and Yale’s principal investigator of the II-ON
team. “The hope is this early research can someday inform clinical
trials and ultimately help us to achieve our goal of transforming
the way we treat people affected by cancer.”
The II-ON was formed on the foundation of three fundamental
scientific pillars aimed at addressing key research priorities in
I-O: understanding the mechanisms of resistance to immunotherapy;
identifying patient populations likely to benefit from
immunotherapy; and exploring novel combination therapies that may
enhance anti-tumor response through complementary mechanisms of
action. By providing a streamlined framework for peer-to-peer
collaboration among global cancer research leaders, the network is
able to more rapidly facilitate I-O innovation and drug
discovery.
“Translational medicine and the understanding of cancer biology
are foundational to our oncology R&D program, which is why
we’re invested in furthering our understanding of early I-O science
through the II-ON,” said Nils Lonberg, head of Oncology Biology
Discovery at Bristol-Myers Squibb. “By adding Yale Cancer Center to
the network, we are strengthening our collective ability to address
essential scientific questions and advance clinical discovery,
which we hope will eventually translate to meaningful outcomes for
patients.”
Bristol-Myers Squibb believes the future of cancer research is
dependent on investments in science and partnerships. In addition
to the II-ON, the company has invested in several other models of
scientific collaboration with academic partners across the globe,
including the Global Expert Centers Initiative (GECI), the
Immuno-Oncology Integrated Community Oncology Network (IO-ICON) and
the Oncology Academic Research (OAR) Group.
About the International Immuno-Oncology
Network (II-ON)
The II-ON, formed in 2012, is a global peer-to-peer
collaboration between Bristol-Myers Squibb and academia advancing
the science of Immuno-Oncology (I-O) through a series of
preclinical, translational and biology-focused research objectives.
The research in the collaboration is focused on three fundamental
scientific pillars: understanding the mechanisms of resistance to
immunotherapy; identifying patient populations likely to benefit
from immunotherapy; and exploring novel combination therapies that
may enhance anti-tumor response through complementary mechanisms of
action. The II-ON facilitates the translation of early scientific
research findings into clinical trials and drug discovery, with the
goal of one day introducing new treatment options into clinical
practice.
In addition to Bristol-Myers Squibb, the II-ON currently
comprises 16 leading cancer research institutions, including:
Clinica Universidad Navarra, Dana-Farber Cancer Institute, The
Earle A. Chiles Research Institute (Providence Health &
Services), Institut Gustave Roussy, Istituto Nazionale per lo
Studio e la Cura dei Tumori “Fondazione G. Pascale”,
Bloomberg-Kimmel Institute for Cancer Immunotherapy at the Johns
Hopkins Kimmel Cancer Center, Memorial Sloan Kettering Cancer
Center, National Cancer Center Japan, The Netherlands Cancer
Institute, The Royal Marsden NHS Foundation
Trust and The Institute of Cancer Research, University
College London, The University of Chicago, West German Cancer
Center/University Hospital Essen, Columbia University Medical
Center, Peter MacCallum Cancer Centre, and now, Yale Cancer
Center.
Bristol-Myers Squibb &
Immuno-Oncology: Advancing Oncology Research
At Bristol-Myers Squibb, patients are at the center of
everything we do. Our vision for the future of cancer care is
focused on researching and developing transformational
Immuno-Oncology (I-O) medicines for hard-to-treat cancers that
could potentially improve outcomes for these patients.
We are leading the scientific understanding of I-O through our
extensive portfolio of investigational compounds and approved
agents. Our differentiated clinical development program is studying
broad patient populations across more than 50 types of cancers with
14 clinical-stage molecules designed to target different immune
system pathways. Our deep expertise and innovative clinical trial
designs position us to advance I-O/I-O, I-O/chemotherapy,
I-O/targeted therapies and I-O/radiation therapies across multiple
tumors and potentially deliver the next wave of therapies with a
sense of urgency. We also continue to pioneer research that will
help facilitate a deeper understanding of the role of immune
biomarkers and how patients’ tumor biology can be used as a guide
for treatment decisions throughout their journey.
We understand making the promise of I-O a reality for the many
patients who may benefit from these therapies requires not only
innovation on our part but also close collaboration with leading
experts in the field. Our partnerships with academia, government,
advocacy and biotech companies support our collective goal of
providing new treatment options to advance the standards of
clinical practice.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb’s business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb’s Annual Report on Form 10-K for the year ended December 31,
2017 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180226005064/en/
Bristol-Myers SquibbMedia:Rose Weldon,
215-801-7644rose.weldon@bms.comorYale Cancer Center:Anne
Doerranne.doerr@yale.edu
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024